J&J’s Ottava Robot Meets Goals in Gastric Bypass Study

Why It Matters

Ottava’s successful trial removes key barriers to robotic adoption—space constraints and safety concerns—positioning J&J to capture market share from da Vinci and accelerate growth in its med‑tech business.

Key Takeaways

• Ottava achieved zero device‑related adverse events in 30 gastric bypass cases
• Study showed average 30‑pound weight loss within 30 days post‑surgery
• Four‑arm design fits operating rooms as small as 243 sq ft
• J&J aims U.S. launch by year‑end pending FDA clearance

Pulse Analysis

The surgical robotics sector, long dominated by Intuitive Surgical’s da Vinci platform, is entering a new phase as legacy medical giants launch their own systems. Johnson & Johnson’s Ottava robot, unveiled in early 2026, promises a modular architecture that integrates four arms directly onto a standard operating table, eliminating the bulky boom that characterizes many competitors. By targeting a de novo FDA classification that spans gastric bypass, sleeve gastrectomy, small‑bowel resection and hiatal hernia repair, J&J positions Ottava as a versatile alternative for general surgeons seeking cost‑effective, high‑precision tools.

The recent multicenter trial of 30 patients undergoing Roux‑en‑Y gastric bypass provides the first clinical validation of Ottava’s safety and efficacy claims. Participants lost an average of 30 pounds within 30 days, and the study reported zero device‑related adverse events, with all procedures completed robotically and no conversions to open surgery. Notably, the system performed in operating rooms ranging from 243 to 694 square feet, some of which had never housed a robot before, demonstrating that the compact design can overcome traditional space barriers that have limited adoption in community hospitals.

If the FDA grants clearance later this year, Ottava could become a catalyst for accelerated growth in J&J’s med‑tech division, which has been seeking to diversify beyond its established orthopaedic and cardiovascular portfolios. The robot’s broader procedural indication set and its ability to retrofit existing ORs may attract midsize health systems looking to add robotic capabilities without the capital outlay required for larger platforms. Analysts anticipate that increased competition will drive price pressure and spur further innovation, ultimately expanding patient access to minimally invasive surgery across the United States.